Texas Health Resources, Arlington, Texas, and insurer Blue Cross and Blue Shield of Texas announced talks to form an accountable care organization.
Ronald Long, chief financial officer and executive vice president of resource development and deployment for the 13-hospital system, said a final agreement is expected in July and the newly formed ACO would launch Jan. 1, 2014.
Long said details such as cost-saving targets have yet to be finalized, but the agreement will tie performance payments to quality and cost controls. Blue Cross and Blue Shield of Texas patients who are treated by Texas Health Resources' employed primary-care physicians will be covered by the accountable care agreement, he said.
Read the full story: http://bit.ly/TY12ua
Source: ModernHealthcare.com
What Will AI in Health Care Look Like in the Future?
July 10th 2025Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and shaping future health care training, as discussed by experts at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen